efavirenz/emtricitabine/tenofovir vs simvastatin

According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.

Side-by-side comparison of efavirenz/emtricitabine/tenofovir and simvastatin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.

minor Known Drug Interaction

HMG-CoA reductase inhibitors: Atorvastatin Pravastatin Simvastatin ↓ atorvastatin * ↓ pravastatin * ↓ simvastatin * Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased.

Drug Class
efavirenz/emtricitabine/tenofovir NNRTI / NRTI Combination
simvastatin HMG-CoA Reductase Inhibitor (Statin)
Type
efavirenz/emtricitabine/tenofovir Prescription
simvastatin Prescription
Summary
efavirenz/emtricitabine/tenofovir

Efavirenz is a drug used to treat HIV-1 infection. It belongs to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTI).

simvastatin

No summary available.

What It Treats
efavirenz/emtricitabine/tenofovir

Efavirenz is used to treat HIV-1, the virus that causes AIDS. It helps to lower the amount of virus in your body. This medicine must be used with other HIV medicines.

simvastatin

Information not available.

How It Works
efavirenz/emtricitabine/tenofovir

Efavirenz blocks an enzyme called reverse transcriptase. HIV needs this enzyme to make copies of itself. By blocking it, efavirenz helps to slow down the spread of HIV in your body.

simvastatin

Information not available.

Common Side Effects
efavirenz/emtricitabine/tenofovir
  • Rash
  • Dizziness
  • Nausea
  • Headache
  • Fatigue
simvastatin
  • Headache
  • Upper respiratory tract infection
  • Muscle pain
  • Diarrhea
FAERS Reports
efavirenz/emtricitabine/tenofovir
  • Virologic Failure 952
  • Drug Interaction 748
  • Drug Resistance 735
  • Viral Mutation Identified 674
  • Pathogen Resistance 623
simvastatin
  • Fatigue 13,574
  • Nausea 12,945
  • Dyspnoea 12,431
  • Diarrhoea 11,813
  • Dizziness 10,971
Serious Warnings
efavirenz/emtricitabine/tenofovir

Efavirenz can cause serious side effects, including psychiatric problems like depression or suicidal thoughts. Tell your doctor right away if you have any of these symptoms. Efavirenz can also harm your liver. Your doctor should check your liver function before and during treatment. Do not take efavirenz by itself.

simvastatin

No specific warnings noted.

Pregnancy
efavirenz/emtricitabine/tenofovir

Efavirenz can harm your unborn baby, especially during the first 3 months of pregnancy. Talk to your doctor about using birth control while taking this medicine. Breastfeeding is not recommended while taking efavirenz.

simvastatin

No pregnancy information available.

Also Compare, Nearby Drugs

How to Read This efavirenz/emtricitabine/tenofovir vs simvastatin Comparison

efavirenz/emtricitabine/tenofovir is classified in the NNRTI / NRTI Combination drug class, while simvastatin sits within the HMG-CoA Reductase Inhibitor (Statin) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.

Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, efavirenz/emtricitabine/tenofovir has 3,732 submissions while simvastatin has 61,734. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to this combination causes the cholesterol medicine to be cleared from your body faster than usual.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.

A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for efavirenz/emtricitabine/tenofovir or simvastatin.

Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.